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OBJECTIVE—Common variants in FTO (the fat mass– and
obesity-associated gene) associate with obesity and type 2 dia-
betes. The regulation and biological function of FTO mRNA
expression in target tissue is unknown. We investigated the
genetic and nongenetic regulation of FTO mRNA in skeletal
muscle and adipose tissue and their influence on in vivo glucose
and fat metabolism.
RESEARCH DESIGN AND METHODS—The FTO rs9939609
polymorphism was genotyped in two twin cohorts: 1) 298 elderly
twins aged 62–83 years with glucose tolerance ranging from
normal to type 2 diabetes and 2) 196 young (25–32 years) and
elderly (58–66 years) nondiabetic twins examined by a hyperin-
sulinemic-euglycemic clamp including indirect calorimetry. FTO
mRNA expression was determined in subcutaneous adipose
tissue (n  226) and skeletal muscle biopsies (n  158).
RESULTS—Heritability of FTO expression in both tissues was
low, and FTO expression was not influenced by FTO rs9939609
genotype. FTO mRNA expression in skeletal muscle was regu-
lated by age and sex, whereas age and BMI were predictors of
adipose tissue FTO mRNA expression. FTO mRNA expression in
adipose tissue was associated with an atherogenic lipid profile.
In skeletal muscle, FTO mRNA expression was negatively asso-
ciated to fat and positively to glucose oxidation rates as well as
positively correlated with expression of genes involved in oxida-
tive phosphorylation including PGC1.
CONCLUSIONS—The heritability of FTO expression in adipose
tissue and skeletal muscle is low and not influenced by obesity-
associated FTO genotype. The age-dependent decline in FTO
expression is associated with peripheral defects of glucose and
fat metabolism. Diabetes 58:2402–2408, 2009
Obesity and type 2 diabetes are heterogenousdisorders caused by both nongenetic and ge-netic components. Recent studies identifiedcommon variants in FTO (the fat mass– and
obesity-associated gene) to be associated with obesity and
type 2 diabetes in humans (1–5). The FTO genotype is
suggested to be involved in the regulation of appetite and
body weight (2,6–8) and may regulate transcription of
genes involved in metabolism by nucleic acid demethyl-
ation (6). In addition, we demonstrated an association
between the FTO genotype on one hand and increased
energy efficiency and elevated blood glucose on the other,
suggesting peripheral effects of FTO (9). A recent paper
demonstrated that inactivation of the FTO gene protects
from obesity in mice and supported the idea of FTO being
involved in peripheral energy homeostasis, mitochondrial
coupling, and/or substrate cycling (10). Thus, the associa-
tion between FTO and obesity may not only involve
control of appetite. Indeed, skeletal muscle and adipose
tissue are important organs in the pathogenesis of obesity,
insulin resistance, and type 2 diabetes.
Few studies have investigated the mRNA expression
levels and biological function of FTO in human adipose
tissue. In one study, expression levels of FTO mRNA was
threefold higher in human subcutaneous adipose tissue
(SAT) than in visceral adipose tissue (VAT) (11), whereas
FTO expression decreased during adipocyte differentia-
tion and was similar in SAT and VAT in another study (12).
In our recent study, we were unable to document any
impact of the FTO genotype on the expression of FTO in
skeletal muscle (9). However, the number of subjects in
this study was limited, and we are unaware of other
studies that have investigated the FTO expression in
human skeletal muscle and its putative peripheral role in
glucose metabolism. The aim of the present study was to
investigate the genetic versus nongenetic regulation of
FTO mRNA expression in skeletal muscle and SAT and to
study the impact of tissue FTO mRNA levels on obesity
and insulin resistance in two twin cohorts.
RESEARCH DESIGN AND METHODS
The FTO rs9939609 polymorphism was genotyped in two cohorts of Danish
twins: 1) a population-based cohort of 298 elderly twins (mean age 74  5
years) and 2) a cohort of 110 young (age 28 2 years) and 86 elderly (age 62
2 years) twins without known type 2 diabetes. The subjects were identified
through the Danish Twin Register, and all procedures were performed
according to the Declaration of Helsinki and approved by the scientific ethics
committees for the counties of Funen and Vejle. The recruitment and details
of selection of cohorts 1 and 2 are previously described (13–16). In cohort 1,
57% were normal glucose tolerant (NGT), 27% had impaired glucose tolerance
(IGT), and 16% had type 2 diabetes. In cohort 2, 74% had NGT, 22.0% had IGT,
and 4% had previously unknown type 2 diabetes among elderly twins. Among
the young twins, 98% had NGT and 2% had IGT.
Clinical examinations. In cohort 1 the subjects were examined with a
standardized 75-g oral glucose tolerance test (OGTT) and BMI and waist-to-
hip ratio (WHR) were measured as previously described (15,16). In addition,
a SAT biopsy was taken from the abdomen under local anesthesia using a
Bergstrom needle, and the tissue was immediately frozen in liquid nitrogen
and stored at 80°C. We were able to obtain adipose tissue biopsies and
measure mRNA FTO expression in a subgroup of 226 twins.
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In cohort 2 the subjects underwent a 2-day clinical examination as
described previously (13,17). Day 1 included an OGTT, anthropometric
measures, and a dual-energy X-ray absorptiometry (DEXA) scan to determine
body composition, and physical fitness was estimated as VO2max calculated
from the maximal load on ergometer bicycle (18). On day 2, a 2-h hyperinsu-
linemic-euglycemic clamp (40 mU/m2 per min) with tritiated glucose preceded
by a 30-min intravenous glucose tolerance test was performed. Indirect
calorimetry was performed during both the basal and insulin-stimulated
steady-state period using a computerized flow-through canopy gas analyzer
system (Deltarac; Datex, Helsinki, Finland). After an equilibrium period of 10
min, the average gas exchange rates were used to calculate the basal and
insulin-stimulated fat and glucose oxidation rates (19,20). The respiratory
coefficient, which is the quotient of CO2 production and O2 consumption,
reflecting the macronutrient being oxidized, was obtained from the calorim-
etry data. Before and after the hyperinsulinemic-euglycemic clamp, skeletal
muscle biopsies were excised from the vastus lateralis muscle under local
anesthesia using a Bergstrom needle, and the tissue was immediately frozen in
liquid nitrogen and stored at 80°C. We were able to measure FTO mRNA
expression in 159 basal and 158 insulin-stimulated skeletal muscle biopsies.
Analytical methods and calculations. Plasma glucose and insulin concen-
trations during the OGTT and the hyperinsulinemic-euglycemic clamp were
analyzed as previously described (15,21). The fasting blood samples were
analyzed for serum triglycerides, total cholesterol, HDL cholesterol, and LDL
cholesterol as previously described (22). Homeostasis model assessment–
insulin resistance was calculated as [(fasting plasma insulin  fasting plasma
glucose)/22.5]  0.144 (23). Calculation of hepatic glucose production, glu-
cose disposal, and insulin secretion has been described previously (13,17).
Glucose and fat oxidation rates were calculated with data obtained from the
indirect calorimetry using the following equations: glucose; 4.55 VCO2 (L/min)
– 3.21VO2 (L/min) – 2.87 n (g/min) and fat; 1.67 VO2 (L/min) – 1.67 VCO2 (L/min)
– 1.92 n (g/min), where n is nitrogen secreted in the urine (19). Glucose and
lipid oxidation data are expressed as milligrams per kilograms of fat-free mass
per minute.
Measurement of gene expression using real-time RT-PCR. Total RNA
was extracted from frozen skeletal muscle and adipose tissue samples using
the Tri Reagent kit according to the manufacturer’s instructions (Sigma-
Aldrich). cDNA was synthesized using the QuantiTect Reverse Transcription
kit (Qiagen). FTO mRNA levels were quantified using TaqMan Real-Time PCR
with an ABI 7900 system (Applied Biosystems) and an Assay-on-demand
(Hs01057145_m1) covering exon 8–9. All samples were run in duplicates and
data were calculated using the standard curve method and normalized to the
mRNA level of cyclophilin A (4326316E, Applied Biosystems). An additional
endogenous control gene, hypoxanthine-guanine phosphoribosyltransferase
(4333768E, Applied Biosystems), was initially analyzed in the skeletal muscle
biopsies. The expression of cyclophilin A as well as the ratio between
cyclophilin A and hypoxanthine-guanine phosphoribosyltransferase were
compared, and there was no effect of a number of variables tested (i.e., age or
insulin), which is why only one control gene (cyclophilin A) was subsequently
used for the statistical analysis of genetic and q-traits. Expression of three
OXPHOX genes, PGC1-, and GLUT4 in vastus lateralis were previously
performed with assays from Applied Biosystems: NDUFB6 (Hs00159583),
UQCRB (Hs00559884), ATP50 (Hs00426889), PGC-1 (Hs00173304), and
GLUT4 (Hs00168966) (24,25).
Genotyping. The FTO polymorphism rs9939609 was genotyped using Taq-
man allelic discrimination (KBioscience, Hertz, U.K.) and obeyed Hardy-
Weinberg equilibrium in both cohort 1 (P  0.44) and cohort 2 (P  0.99). The
overall genotyping success rate was 97.4%. The minor allele frequency for FTO
rs9939609 was 37.3% (33.3;41.3) and 39.1% (34.2;43.9) in cohorts 1 and 2,
respectively.
Statistical methods. Comparison of FTO mRNA expression between young
and elderly twins and comparison between FTO genotype and FTO mRNA
expression were done by a mixed-effects regression model. Correlation
analyses were made using the Pearson’s correlation coefficient test with
ln-transformed data. Multiple regression analyses were performed to test the
influence of potential factors on FTO mRNA expression in adipose tissue and
skeletal muscle and to test the impact of FTO mRNA expression on in vivo
metabolism. In all the multiple regression analyses, the outcome variable was
ln transformed. We tested the influence of the following variables on FTO
mRNA expression in skeletal muscle: age (elderly [1] or young [2]), sex (men
[1] or women [2]), zygosity status (MZ [monozygotic] [1] or DZ [dizygotic] [2]),
total fat percentages (continuous percent), and total body aerobic capacity
VO2max (continuous [ml  kg
1  min1]) and in adipose tissue: age (continuous
years), sex (men [1] or women [2]), zygosity status (MZ [1] or DZ [2]), and BMI
(continuous [kg/m2]). Both models took into account that the observations
within twins cannot be assumed to be independent and that the dependency
effects are different for MZ and DZ twin pairs. Thus, the full models include a
random-effects term for twin pair membership and a fixed-effects term for
zygosity. Because MZ twins have identical genotypes, any differences are
theoretically because of environmental factors, whereas DZ twins, on average,
share 50% of their genes. The extent to which MZ twins are more alike than DZ
twins is presumed to reflect a genetic influence on the phenotype in question.
Heritability (expressed as h2) gives the proportion of the total variation of a
trait attributable to genetic variation and can be estimated by comparing the
similarity (i.e., intraclass correlations) of a given phenotype between MZ and
DZ twin pairs. Statistical comparisons of intraclass correlations were made
after transformation using the Fisher z transformation. The heritability is
expressed as twice the difference of the intraclass correlation of MZ and DZ
twins h2  2(rMZ – rDZ) (26). The designation of a member in a twin pair is
arbitrary; i.e., there is no consistency in which of the twins in a pair is assigned
A and which is assigned B. The correlation coefficient may differ dependent on
the assignment of the twins, and randomization is required. To avoid the
randomization procedure, intrapair correlations were calculated using 2n, as
previously recommended (27). All analyses were carried out in SAS (version
9.1; SAS Institute); P  0.05 was considered significant.
RESULTS
The clinical characteristics of the two cohorts are shown
in Table 1. The A-allele of FTO rs9939609 was associated
to measures of obesity, namely BMI (TT: 25.2  0.3, AT:
26.1  0.1, AA: 27.1  0.6; P  0.03) in cohort 1 and WHR
in cohort 1 (TT: 0.87  0.01, AT: 0.87  0.01, AA: 0.91 
0.01; P  0.004) and in the younger twins in cohort 2 (TT:
0.84  0.02, AT: 0.81  0.01, AA: 0.91  0.02; P  0.004).
No associations between rs9939609 and either BMI (P 
0.93) or WHR (P  0.92) were observed in the elderly
twins in cohort 2. Furthermore, the A-allele of FTO
rs9939609 was associated with reduced insulin-stimulated
TABLE 1
Subject characteristics
Cohort 1 Cohort 2
Elderly Young Elderly
n (men/women) 226 (103/123) 110 (60/50) 86 (38/48)
n (MZ/DZ) 226 (92/134) 110 (66/44) 86 (42/44)
Age (years) 73.4  5.3 28  2 62  2
BMI (kg/m2) 26.1  3.7 24.1  3.1 26.1  4.5
WHR 0.90  0.1 0.84  0.08 0.89  0.1
Total fat (%) NA 22.1  7.0 27.9  9.4
Vo2max (ml  kg
1  min1) NA 39.6  7.8 26.3  7.0
Basal GOX (mg  kg FFM1  min1) NA 114  55 90  52
Insulin-stimulated GOX (mg  kg FFM1  min1) NA 246  24 200  28
Basal FOX (mg  kg FFM1  min1) NA 69  26 70  24
Insulin-stimulated FOX (mg  kg FFM1  min1) NA 20  24 62  24
Insulin sensitivity (Rd) (mg  kg FFM1  min1) NA 11.7  1.9 9.9  3.3
Data are expressed as means  SD. NA, not appilicable; FFM, fat-free mass; FOX, fat oxidation; GOX, glucose oxidation.
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glucose uptake (TT: 12.0  0.6, AT: 11.9  0.5, AA: 9.9 
0.8; P  0.07) and nonoxidative glucose metabolism (TT:
8.0  0.6, AT: 7.3  0.5, AA: 5.3  0.7; P  0.01) in the
young (and not elderly) twins of cohort 2. However, these
associations disappeared after adjustment for BMI. No
association between rs9939609 and basal or insulin-stim-
ulated glucose or fat oxidation was observed in either the
young or elderly twins.
Young twins had significantly higher muscle FTO mRNA
levels compared with elderly twins both in the basal state
(2.73  0.95 vs. 1.97  0.77, P  0.0001) and after insulin
stimulation (2.61  0.80 vs. 2.01  0.82, P  0.0004) (Fig.
1). The expression level of FTO mRNA did not change
significantly by insulin stimulation in the group of all twins
(P  0.27) or in the subgroups of young (P  0.12) and
elderly (P  0.86) twins, which is why only the mRNA
expression levels during the basal state were used in the
subsequent analyses.
Genetic influence on FTO expression in skeletal
muscle and adipose tissue. We studied the association
between FTO rs9939609 and FTO mRNA expression and
found no significant association in either skeletal muscle
or in adipose tissue (Table 2). Upon adjustment for age
and sex in the analysis the association remained nonsig-
nificant (P  0.90 and P  0.28, respectively). The intra-
class correlations for FTO expression in skeletal muscle
were similar in MZ (r 0.72) and DZ twins (r 0.57) (P
0.28), with a heritability estimate of 0.30. In adipose tissue,
the intraclass correlations for FTO expression in MZ were
r  0.30 and in DZ r  0.25 (P  0.83) with a heritability
estimate of 0.10.
Nongenetic predictors of FTO mRNA expression
Skeletal muscle. This study aimed to identify nongenetic
determinants of FTO mRNA expression including obesity
and physical fitness, and correlation analyses were per-
formed between FTO mRNA in skeletal muscle and total
fat percentages (r  0.35, P  0.0001) and VO2max (r 
0.41, P  0.0001). To quantify the independent effect of
these variables on FTO mRNA expression, multiple regres-
sion analyses with the additional inclusion of age, sex, and
zygosity were performed. Age (exp[]  0.72, P  0.0001)
and sex (exp[]  1.27, P  0.002) were the only signifi-
cant independent predictors of FTO mRNA expression in
skeletal muscle (Table 3). Thus, being an elderly twin is
associated with a 28% decrease in FTO mRNA expression
and being a male is associated with a 27% increase in FTO
mRNA expression.
Adipose tissue. Similarly, multiple regression analyses
were performed to quantify the effect of age, sex, zygosity,
and BMI on the level of FTO mRNA expression in adipose
tissue. Age (exp[]  0.92, P  0.002) and BMI (exp[] 
1.13, P  0.0001) were significant independent predictors
of FTO mRNA expression in adipose tissue. A 1 SD
increase in age (5.1 years) results in an 8% decline in FTO
mRNA and a 1 SD increase in BMI (4.3 kg/m2) results in a
13% increase in FTO mRNA level (Table 4).
Impact of FTO mRNA expression on in vivo
metabolism
Skeletal muscle. To investigate the relationships be-
tween FTO mRNA expression and in vivo metabolism,
regression analyses were made with FTO mRNA expres-
sion levels as the explanatory variable. Based on the above
findings the analyses were adjusted for age and sex. The
expression of FTO mRNA had a significant impact on both
the basal and insulin-stimulated fat oxidation rate. An
increase in FTO mRNA level of 1 SD (0.78 AU) was
associated with a 12% (P  0.04) decrease in basal
fat oxidation and 18% (P  0.03) decrease in insulin-
stimulated fat oxidation (Table 5). In addition, an increase
of 1 SD in FTO expression was associated with a border-
line significant increase of 10% (P  0.07) in basal glucose
oxidation and with a 1% increase in basal respiratory
coefficient (P  0.03) and insulin-stimulated respiratory
coefficient (P  0.03) (Table 5). The associations between
FTO mRNA and fat oxidation remained significant after
adjustment for total fat mass and percentage. No influence
of skeletal muscle FTO mRNA expression on peripheral
insulin sensitivity, hepatic glucose production, insulin
secretion, energy expenditure, or VO2max was observed
(data not shown). Because of the putative effects on lipid
and/or glucose oxidation, we investigated associations
between FTO mRNA expression and expression of genes
involved in mitochondrial function including OXPHOS
genes and their key regulator PGC-1. Significantly posi-
tive correlations between FTO expression and the OX-
PHOS genes NDUFB6 (r 0.48, P 0.0001), UQCRB (r
0.48, P  0.0001), ATP50 (r  0.62, P  0.0001), and the
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FIG. 1. FTO mRNA expression in skeletal muscle obtained before and
after insulin stimulation in young () and elderly (f) twins. Results
are expressed as means  SD; mRNA levels were quantified with
real-time PCR and normalized to the level of Cyclophilin A. After
adjusting for intratwin pair relationship, P < 0.0001 for basal expres-
sion (left panel) and P  0.0004 for post-clamp expression (right
panel).
TABLE 2
Association between FTO rs9939608 genotype and FTO mRNA expression in skeletal muscle and adipose tissue
Skeletal muscle n TT n AT n AA P
Basal FTO expression 60 2.28  0.81 76 2.26  0.82 22 2.51  1.31 0.46
Basal adipose tissue
FTO expression 77 0.96  0.38 108 0.89  0.38 26 0.96  0.39 0.37
Data are expressed as means  SD.
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PPAR- coactivator 1- (PGC-1) (r  0.44, P  0.0001)
(Fig. 2) in skeletal muscle were found. Despite no effect of
FTO expression on whole-body glucose uptake, FTO
mRNA was significantly and positively correlated to
GLUT4 mRNA (r  0.46, P  0.0001).
Adipose tissue. Using univariate analyses we found that
FTO mRNA was correlated with fasting serum levels of
total LDL (r  0.17, P  0.009) and HDL (r  0.21, P 
0.001) cholesterol. When adjusted for age and BMI, the
observed independent predictors of FTO mRNA in adipose
tissue in the present study, the association with HDL and
LDL cholesterol remained significant. A 1-SD increase in
FTO mRNA (0.35 AU) was associated with a 12% (P 
0.02) decrease in HDL cholesterol levels and a 5% (P 
0.02) increase in LDL cholesterol levels. No impact of FTO
expression in adipose tissue was seen on either glucose
tolerance (2-h post-OGTT plasma glucose) or indirect
measures of insulin sensitivity (homeostasis model
assessment–insulin resistance) (data not shown). Like-
wise, FTO mRNA expression did not differ among twins
stratified according to glucose tolerance: NGT (n  125)
0.94  0.36; IGT (n  62) 0.89  0.38; type 2 diabetes (n 
37) 0.94  0.30.
DISCUSSION
Variations in FTO have been associated with obesity and
type 2 diabetes, but the biological functions and regulation
of FTO mRNA expression in human tissues still remain to
be clarified. Contributing to the sparse knowledge of
human FTO mRNA expression, our key findings of the
present study were that 1) the obesity-associated FTO
rs9939609 does not influence tissue FTO mRNA expres-
sion in human skeletal muscle and adipose tissue in the
basal state; 2) heritability of FTO mRNA expression is low;
3) accordingly, FTO mRNA expression in the basal state is
mainly regulated by nongenetic factors in both skeletal
muscle (age and sex) and adipose tissue (age and BMI);
and 4) FTO mRNA expression in skeletal muscle corre-
lates with whole-body substrate oxidation rates.
We found no associations between the examined FTO
genotype and tissue FTO mRNA expression, indicating
that the FTO genotype has no major or direct role in the
regulation of FTO mRNA in either adipose tissue or
skeletal muscle in the present study samples. The lack of
association between the FTO polymorphism and level of
mRNA expression is supported by our observation of a
low heritability estimate of FTO mRNA expression in both
adipose and skeletal muscle tissue. These findings do not,
however, exclude that FTO genotype may influence the
biological function of FTO in terms of activity. Previous
findings (11,12) are in line with the present, although a
recent study indeed has shown an association between
FTO genotype and mRNA expression in SAT in very obese
(BMI 40 kg/m2) subjects (28). Therefore, it cannot be
excluded that a potential effect of genotype on tissue FTO
mRNA expression levels may be unmasked in extreme
states of metabolic disease such as severe obesity or upon
certain challenges including exercise or dietary interven-
tions. In fact, this was the case in a recent study demon-
strating that insulin resistance per se was associated with
a markedly reduced expression of PGC-1 in skeletal
muscle only after an acute exercise bout (29). Moreover, it
is possible that the polymorphism analyzed in this study,
located in intron 1 of the FTO gene, may affect the
expression pattern of the splice variants of FTO, which
may vary in different tissues. The assay used in this study
covers exon 8–9 and can detect three different splice
variants. However, it does not distinguish between these
variants. This question should be addressed in future ad
hoc studies.
We showed that FTO expression in SAT decreased by
8% for every 5 years increase in age. Opposed to this
finding, a study has shown that FTO expression in subcu-
taneous and visceral fat increased with age (11); this
TABLE 3
Variables with possible influence on FTO mRNA expression in vastus lateralis muscle
Estimate 95% CI
Percent
change
Effect of
1 SD
Percent
change P
Basal FTO mRNA level
Age (elderly vs. young) 0.72 (0.64–0.82) 228% — — 0.0001
Sex (men vs. women) 1.27 (1,12–1.43) 127% — — 0.002
Zygosity (MZ vs. DZ) 1.08 (0.98–1.20) 18% — — 0.11
Total fat (%) 1.00 (0.99–1.01) — 0.99 21% 0.82
Vo2max (ml  kg
1  min1) 0.99 (0.99–1.00) 21% 0.97 23% 0.42
Model: ln FTO adjusted for age, sex, zygosity, total fat percentages, and Vo2max. SD: adjusted for total fat percentage 8.65, Vo2max  9.62.
P values are adjusted for twin pair and zygosity status.
TABLE 4
Variables with possible influence on FTO mRNA expression in adipose tissue
Estimate 95% CI
Percent
change
Effect of
1 SD
Percent
change P
Basal FTO mRNA level
Age (years) 0.98 (0.97–0.99) 22% 0.92 28% 0.002
Sex (men vs. women) 1.09 (0.97–1.21) 19% — — 0.13
Zygosity (MZ vs. DZ) 0.96 (0.85–1.09) 24% — — 0.56
BMI (kg/m2) 1.03 (1.02–1.04) 13% 1.13 113% 0.0001
Model: ln FTO  adjusted for age, sex, zygosity, and BMI. SD: adjusted for age  5.14, BMI  4.26. P values are adjusted for twin pair and
zygosity status.
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association disappeared, however, after adjustment for
BMI. This discrepancy may be because of the narrow age
range within the cohort of elderly twins in our study that
in addition may limit generalization to younger individuals.
Nevertheless, the findings are in line with those in skeletal
muscle FTO expression, providing some support to a
decrease in adipose tissue FTO expression with age. The
few human studies of FTO expression in adipose tissue
performed so far have been inconsistent concerning the
relationship between obesity and FTO tissue expression.
We found that the expression of FTO in adipose tissue was
positively associated with obesity as measured by BMI,
supporting some (12,28,30) but not all studies (11). A study
in mice showed that FTO mRNA expression was 50%
lower in adipocytes from db/db mice (a genetic model of
obesity and type 2 diabetes) compared with wild-type mice
(31). Independent of obesity, we demonstrated that in-
creased FTO mRNA expression in adipose tissue was
associated with an atherogenic serum lipid profile includ-
ing an increase in circulating levels of LDL cholesterol and
a decrease in HDL cholesterol levels. A previous study has
demonstrated a borderline correlation between SAT FTO
mRNA abundance and plasma glycerol, although no asso-
ciation to lipolysis was evident (12). FTO expression in
adipose tissue was not influenced by glucose tolerance
status and was not related to OGTT-derived measures of
insulin sensitivity or insulin release. The lack of associa-
tion between adipose tissue FTO expression and glucose
metabolism is in accordance with a previous study of 55
Europeans (11).
FTO mRNA abundance in skeletal muscle was reduced
by 28% in elderly compared with younger twins and
significantly associated with in vivo measures of basal and
insulin-stimulated fat oxidation and respiratory coefficient,
in addition to a borderline significant association with
glucose oxidation rate. These metabolic associations were
independent of total fat mass and percentage, and collec-
tively they point toward a shift from glucose to fat
oxidation with an age-related decrease in FTO muscle
expression. Because we previously demonstrated an
age-related reduction in the mRNA expression of genes
involved in oxidative phosphorylation (24), present ex-
pression data were adjusted for PGC-1 expression levels.
Interestingly, the association between FTO mRNA expres-
sion in skeletal muscle and fat oxidation was persistent
and independent of PGC-1 expression levels during both
the basal (P  0.08) state and after insulin stimulation
(P  0.05). Therefore, the age-related decline in skeletal
muscle FTO expression may at least to some extent
explain the higher fat oxidation rate among elderly twins.
The association between fat mass and fat oxidation is
complex, with low fat oxidation potentially being causally
related to risk of accumulating fat on one side and with fat
accumulation in obesity potentially leading to increased
fat oxidation as a consequence of excess tissue release of
fatty acids on the other side. Thus, caution is warranted in
the interpretation of cause and effect in these cross-
sectional associations. We have recently reported that the
obesity-associated A-allele of FTO rs9939609 was associ-
ated with increased mitochondrial energy efficiency in
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FIG. 2. Correlation between FTO mRNA and PGC-1 mRNA in skeletal muscle. r  0.44, P < 0.0001.
TABLE 5
The relationship between FTO mRNA expression in skeletal muscle and substrate oxidation
Estimate 95% CI
Percent
change
Effect of
1 SD
Percent
change P
Basal FOX (mg  kg FFM1  min1) 0.85 (0.73–1.00) 215% 0.88 212% 0.04
Clamp FOX (mg  kg FFM1  min1) 0.77 (0.61–0.97) 223% 0.82 218% 0.03
Basal GOX (mg  kg FFM1  min1) 1.12 (0.99–1.28) 112% 1.10 110% 0.07
Clamp GOX (mg  kg FFM1  min1) 1.05 (0.97–1.13) 15% 1.04 14% 0.21
Basal respiratory coefficient 1.02 (1.00–1.03) 12% 1.01 11% 0.03
Clamp respiratory coefficient 1.02 (1.00–1.03) 12% 1.01 11% 0.03
Model: Ln dependent variable  FTO mRNA adjusted for age and sex. SD: Basal FTO mRNA  0.78. P values are adjusted for twin pair and
zygosity status. FOX, fat oxidation; GOX, glucose oxidation.
REGULATION AND FUNCTION OF FTO EXPRESSION
2406 DIABETES, VOL. 58, OCTOBER 2009 diabetes.diabetesjournals.org
skeletal muscle from young healthy men (9). Furthermore,
in accordance with our previous study, we here demon-
strate in a large cohort of young and elderly twins that the
FTO mRNA transcript was associated with the expression
of PGC-1 and mitochondrial OXPHOS genes (9). The
molecular mechanisms and sequences of events linking
mitochondrial (dys)function and lipid oxidation to insulin
resistance, obesity, and type 2 diabetes are incompletely
understood and may involve both accumulation of lipid
per se in muscle and liver as well as accumulation of
by-products because of incomplete fat oxidation (32,33).
Lipid intermediates such as fatty acyl CoA and diacylglyc-
erol can inhibit insulin signaling and reduce glucose
uptake, leading to insulin resistance (32,34).
In conclusion, the age-dependent decline in FTO expres-
sion in adipose tissue and skeletal muscle is associated
with an atherogenic serum lipid profile, as well as with a
shift in in vivo fat and glucose oxidation independent of
obesity and gene expression levels of key metabolic
regulators including PGC-1. FTO expression in adipose
tissue and skeletal muscle may therefore play a role in the
development of some components of the metabolic syn-
drome, including dyslipidemia and peripheral metabolic
regulation.
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